CXXI Overview

Share Buyback Program Announcement: C21 Investments Inc. plans to repurchase approximately 5% of its common shares as part of a share buyback program, which will run for one year starting December 2, 2024, aiming to enhance shareholder value.

Financial Performance and Growth: The company reported a 14% increase in revenue to $7.5 million in the second quarter, with significant sales growth in its South Reno dispensary, indicating strong financial health to support the buyback initiative.

Financial Performance: C21 Investments Inc. reported a revenue of $7.5 million for Q2 2024, marking a 14% increase from the previous quarter, with gross margins rising to 43.5% and positive adjusted EBITDA of $1.3 million.

Dispensary Success: The new South Reno dispensary saw a significant sales increase of 53% in its first quarter, generating $416,000 in September and continuing to grow with $475,000 in October.

Financial Performance: C21 Investments reported a revenue of $6.6 million for the first quarter ending June 30, 2023, marking a slight increase despite a 1% decline in Nevada sales, with gross margins affected by inventory issues related to the launch of a new dispensary.

Operational Highlights: The company experienced a net loss of $1.4 million but maintained positive cash flow from operations and completed the acquisition of a third dispensary, which was rebranded and became operational at the end of the quarter.

Financial Performance of C21 Investments and Vext Science: Both companies have shown strong financial performance with notable cash flow margins, outperforming larger cannabis firms despite their smaller market caps. C21 Investments has an LFCFM of 12.3%, while Vext Science has 4.1%, indicating efficient revenue conversion into cash.

Credit Rankings and Market Comparison: C21 Investments and Vext Science rank highly in credit stability within the small-cap cannabis sector, with C21 at #2 and Vext at #1. Their ability to manage debt is reflected in their low total liabilities to market cap ratios, contrasting sharply with the significantly higher prices of larger competitors like Tilray and Curaleaf.